The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: A feasibility study Journal Article

Authors: Kornblith, A. B.; Herndon, J. E., 2nd; Zuckerman, E.; Godley, P. A.; Savarese, D.; Vogelzang, N. J.; Holland, J. C.
Article Title: The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: A feasibility study
Abstract: Objectives: The quality of life (QoL) of 44 men with HRPC and 37 partners (primary caregivers, most residing with the patient) was assessed in a multicenter Phase II trial of docetaxel, estramustine and low dose hydrocortisone (CALGB 9780). A secondary objective was to test the feasibility of assessing partners' QoL in a cooperative group setting. Patients and methods: Patients and partners were separately interviewed by telephone at baseline, two, four and six months by a single trained research interviewer. Patients' QoL was measured by the FACT-P, Mental Health Inventory-17 (MHI-17), Brief Pain Inventory (BPI), a two-day log of pain medications, and the OARS for co-morbid conditions. Partners' QoL was measured by the MHI-17, Caregiver Burden Interview, and co-morbid conditions. Results: The QoL study refusal rates were low for patients (4%) and partners (3%). Although patients tended to experience greater treatment side effects in the first two months (FACT Physical Well-Being item, P = 0.057), their cancer-specific emotions (e.g., worrying about worsening health) significantly improved at two and four months (FACT-Emotional Well-Being, P = 0.003, P = 0.03, respectively), as did their prostate cancer-specific physical problems (e.g., urination, pain), at two and four months (FACT-P, P = 0.001, P = 0.005, respectively). Partners' anxiety significantly decreased over time (MHI, P < 0.05). Patients' quality of life at two months was significantly related to their clinical response (FACT-P total and prostate cancer-specific problems, P < 0.05), and their clinical response was significantly related to a decrease in their partners' anxiety at two months (MHI, P < 0.05). Conclusions: Despite feeling worse from side effects, patients' prostate cancer-specific problems and emotional state significantly improved in the first four months of treatment. With treatment significantly affecting both patients' and partners' lives, and the successful assessment of partners' QoL, QoL of both patients and partners could be used as important endpoints in selected clinical trials.
Keywords: adult; clinical article; controlled study; treatment outcome; aged; aged, 80 and over; middle aged; clinical trial; side effect; paclitaxel; quality of life; controlled clinical trial; pain; phase 2 clinical trial; antineoplastic combined chemotherapy protocols; cancer pain; drug resistance, neoplasm; docetaxel; prostate cancer; prostatic neoplasms; narcotic analgesic agent; feasibility study; health status; feasibility studies; multicenter study; comorbidity; measurement; emotion; caregiver; taxoids; anxiety; hydrocortisone; hormone; administration, oral; infusions, intravenous; emotions; mental health; drug use; wellbeing; sexual behavior; spouses; micturition; spouse; estramustine; humans; human; male; female; priority journal; article; hormone refractory prostate cancer
Journal Title: Annals of Oncology
Volume: 12
Issue: 5
ISSN: 0923-7534
Publisher: Oxford University Press  
Date Published: 2001-05-01
Start Page: 633
End Page: 641
Language: English
DOI: 10.1023/a:1011102619058
PUBMED: 11432621
PROVIDER: scopus
Notes: Export Date: 21 May 2015 -- Source: Scopus
Citation Impact
MSK Authors
  1. Jimmie C B Holland
    336 Holland